Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck KGaA provides R&D update

Merck KGaA (FSE:MRK) said that following a portfolio review of subsidiary Merck Serono's pipeline, the company will focus R&D activities on cancer, neurodegenerative

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE